Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome

Journal of the American Society of Nephrology

Volumn 9, Issue 8, 1998, Pages 1474-1481

  De Sain Van Der Velden, Monique G M ^d   Reijngoud, Dirk Jan ^d   Kaysen, George A ^a,b   Gadellaa, Mireille M ^d   Voorbij, Hieronymus ^d   Stellaard, Frans ^d   Koomans, Hein A ^d   Rabelink, Ton J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CORONARY RISK; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MALE; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0031927583     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Dahlén GH: Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 108: 111-126, 1994
2. Bartens W, Wanner C: Lipoprotein(a): New insights into an atherogenic lipoprotein. Clin Invest 72: 558-567, 1994
3. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G: Lipoprotein(a) as a strong indicator for cerebrovasular disease. Stroke 17: 942-945, 1986
4. Farrer M, Game FL, Albers CJ, Neil HA, Winocour PH, Laker MF, Adams PC, Alberti KG: Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb 14: 1272-1283, 1994
5. Ridker PM, Stampfer MJ, Hennekens CH: Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273: 1269-1273, 1995
6. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, Konig P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91: 397-401, 1993
7. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86: 475-482, 1992
8. Haffner SM, Gruber KK, Aldrete G Jr, Morales PA, Stern MP, Tuttle KR: Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol 3: 1156-1162, 1992
9. Thillet J, Faucher C, Issad B, Allouache M, Chapman J, Jacobs C: Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 22: 226-232, 1993
10. Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer P, Wieland H: Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 119: 263-269, 1993
11. Kanno H, Saito E, Fujioka T, Yasugi T: Lipoprotein(a) levels in the nephrotic syndrome. Intern Med 31: 1004-1008, 1992
12. Faucher C, Doucet C, Baumelou A, Chapman J, Jacobs C, Thillet J: Elevated lipoprotein(a) levels in primary nephrotic syndrome. Am J Kidney Dis 22: 808-813, 1993
13. Stenvinkel P, Berglund L, Heimburger O, Pettersson E, Alvestrand A: Lipoprotein(a) in nephrotic syndrome. Kidney Int 44: 1116-1123, 1993
14. Joven J, Simo JM, Vilella E, Camps J, Espinel E, Villabona C: Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: Relation to remission of proteinuria. Clin Chim 41: 908-913, 1995
15. Siakotos M, Apostolou T, Papageorgakis N, Nikolopoulou N, Metaxatos G, Anagnostou M, Billis A: Serum Lp(a) in patients with nephrotic syndrome due to idiopathic membranous nephropathy [Abstract]. Nephrol Dial Transplant 8: 930, 1993
16. Karadi I, Romics L, Palos G, Doman J, Kaszas I, Hesz A, Kostner GM: Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 35: 2121-2123, 1989
17. Chan MK, Persaud JW, Varghese Z, Moorhead JF: Post-heparin hepatic and lipoprotein lipase activities in nephrotic syndrome. Aunt N Z J Med 14: 841-847, 1984
18. Yamada M, Matsuda I: Lipoprotein lipase in clinical and experimental nephrosis. Clin Chim Acta 30: 787-794, 1970
19. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL: Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins: Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem 267: 13284-13292, 1992
20. McTigue Argraves K, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK: The atherogenic Lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 2170-2181, 1997
21. de Sain-van der Velden MGM, Kaysen GA, Barrett HA, Stellaard F, Gadellaa MM, Voorbij HAM, Reijngoud DJ, Rabelink TJ: Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 53: 994-1001, 1998
22. de Sain-van der Velden MGM, Kaysen GA, de Meer K, Stellaard F, Voorbij HAM, Reijngoud DJ, Rabelink TJ, Koomans HA: Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: Measurements with stable isotopes. Kidney Int 53: 181-188, 1998
23. Egusa G, Brady DW, Grundy SM, Howard BV: Isopropanol precipitation method for the determination of apolipoprotein B-specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J Lipid Res 24: 1261-1267, 1983
24. Hill RL: Hydrolysis of proteins. Adv Protein Chem 20: 37-107, 1965
25. Kamboh MI, Ferell RE, Kottke BA: Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet 49: 1063-1074, 1991
26. Marcovina SM, Hobbs HH, Albers JJ: Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: Basis for a standardized isoform nomenclature. Clin Chem 42: 436-439, 1996
27. Ernst A, Helmhold M, Brunner C, Petho Schramm A, Armstrong VW, Muller HJ: Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 270: 6227-6234, 1995
28. Hušek P: Rapid derivatization and gas chromatographic determination of amino acids. J Chromatogr 552: 259-299, 1991
29. Foster DM, Barrett PH, Toffolo G, Beltz WF, Cobelli C: Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J Lipid Res 34: 2193-2205, 1993
30. Simulation Analyzing and Modeling Institute: SAAM II User Guide, 1997
31. Kawade M, Maeda S, Abe A, Yamashiro M: Alterations in plasma Lp(a) lipoprotein and acute phase proteins after surgical operation [Abstract]. Clin Chem 30: 941, 1984
32. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C: Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80: 458-465, 1987
33. Morrisett JM, Gaubatz JW, Nava MN, Guyton JR, Hoffman AS, Opekun AR, Hachey DL: Metabolism of apo(a) and apo B100 in human Lipoprotein(a). In: Drugs Affecting Lipid Metabolism, edited by Catapano AL, Gotto AM, Smith LC, Paoletti R, Amsterdam, The Netherlands, Kluwer and Fondazione Giovanni Lorenzini, 1993, pp 161-167
34. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB: Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 91: 443-447, 1993
35. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr: The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 93: 2758-2763, 1994
36. Knight BL: Lp(a) catabolism in hypercholesterolaemic individuals. Chem Phys Lipids 67-68: 233-239, 1994
37. White AL, Rainwater DL, Lanford RE: Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes. J Lipid Res 34: 509-517, 1993
38. Wilkinson J, Munro LH, Higgins JA: Apolipoprotein(a) is not associated with apolipoprotein B in human liver. J Lipid Res 35: 1896-1901, 1994
39. Chiesa G, Hobbs HH, Koschinsky ML, Lawn RM, Maika SD, Hammer RE: Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J Biol Chem 267: 24369-24374, 1992
40. Rainwater DL, Lanford RE: Production of lipoprotein(a) by primary baboon hepatocytes. Biochim Biophys Acta 1003: 30-35, 1989
41. Bonen DK, Hausman AML, Hadjiagapiou C, Skarosi SF, Davidson NO: Expression of a recombinant apolipoprotein(a) in HepG2 cells: Evidence for intracellular assembly of lipoprotein(a). J Biol Chem 272: 5659-5667, 1997
42. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH: Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 87: 2153-2161, 1991
43. Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R, Patsch W: The relation of lipoprotein[a] concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 13: 1558-1566, 1993
44. Gaubatz JW, Ghanem KI, Guevara J Jr, Nava ML, Patsch W, Morrisett JD: Polymorphic forms of human apolipoprotein[a]: Inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a]. J Lipid Res 31: 603-613, 1990
45. Kraft HG, Sandholzer C, Menzel HJ, Utermann G: Apolipoprotein (a) alleles determine lipoprotein (a) particle density and concentration in plasma. Arterioscler Thromb 12: 302-306, 1992
46. Gavish D, Azrolan N, Breslow JL: Plasma Lp(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. J Clin Invest 84: 2021-2027, 1989
47. Brown CD, Azrolan N, Thomas L, Roberts KG, Bostom A, Zhao ZH, Friedman EA: Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome. Am J Kidney Dis 26: 170-177, 1995
48. Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M: Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. Eur J Clin Invest 27: 169-177, 1997
49. Crook MA, Haq S, Chusney G, Haq M, Tutt P: Acute phase proteins and lipoprotein(a) in patients with severe hypercholesterolaemia and normal subjects. Clin Chim Acta 224: 199-201, 1994
50. Constans J, Wendling G, Peuchant E, Camilleri G, Conri C: Lipoprotein(a) in 505 hospitalized patients with various pathological states: Correlations with cardiovascular diseases and therapies. Int Angiol 15: 1-5, 1996
51. Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY: The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta 223: 73-82, 1993
52. Sato H, Suzuki S, Ueno M, Shimada H, Karasawa R, Nishi S, Arakawa M: Localization of apolipoprotein(a) and B-100 in various renal diseases. Kidney Int 43: 430-435, 1993
53. Thiery J, Armstrong VW, Schleef J, Creutzfeldt C, Creutzfeldt W, Seidel D: Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr 66: 462-463, 1988
54. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL: HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 80: 1313-1319, 1989
55. Wanner C, Bohler J, Eckardt HG, Wieland H, Schollmeyer P: Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome. Clin Nephrol 41: 138-143, 1994
56. Gansevoort RT, Heeg JE, Dikkeschei FD, de Zeeuw D, de Jong PE, Dullaart RP: Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 9: 244-250, 1994
57. Berg AL, Nilsson-Ehle P: ACTH lowers serum lipids in steroid-treated hyperlipidemic patients with kidney disease. Kidney Int 50: 538-542, 1996